Introduction. Cisplatin is a chemotherapy drug widely used in the treatment of different types of cancer. However, one of its undesirable side effects is ototoxicity, leading to bilateral sensorineural hearing loss at high frequencies, which is irreversible, with more severe involvement in children up to 5 years of age. Thus, evaluating the peripheral and central auditory system in patients of different age groups submitted to cisplatin is essential, as it may contribute to auditory monitoring and to reduce the impacts of hearing loss. Purpose. To study the auditory pathway of patients of different age groups undergoing chemotherapy treatment with cisplatin.Material e methods. Cross-sectional observational study. Patients seen at the Instituto de Tratamento do Câncer Infantil (ITACI) between two and 18 years of age, undergoing chemotherapy treatment with cisplatin will be included. Patients with prior hearing loss, undergoing radiotherapy, or having undergone chemotherapy previously will be excluded. The procedures include the application of a medical history protocol, immittance testing, Auditory Brainstem Response (ABR), transient evoked otoacustic emissions (TEOAE) and by distortion product (DPOAE), tonal, vocal and high-frequency audiometry. The participants will be evaluated before the beginning of chemotherapy and after three months. Analysis of results. Groups will be formed from pre-defined age groups. The data will be tabulated and statistically analyzed. We will analyze the absolute latency values of waves I, III and V and the interpeaks I-III, III-V and I-V of ABR, the hearing thresholds obtained in tonal and high-frequency audiometry, and the results of TEOAE and DPOAE.
News published in Agência FAPESP Newsletter about the scholarship: